Von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion

Blood

Volumn 119, Issue 20, 2012, Pages 4769-4778

  Madabhushi, Sri R ^a   Shang, Chengwei ^a   Dayananda, Kannayakanahalli M ^a   Rittenhouse Olson, Kate ^b,c   Murphy, Mary ^d   Ryan, Thomas E ^d   Montgomery, Robert R ^e   Neelamegham, Sriram ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d Reichert Inc   (United States)

^e BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB ALPHA; MONOCLONAL ANTIBODY; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CONTROLLED STUDY; HEMOSTASIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 84861208099     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-387548     Document Type: Article

References (46)

1. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007;98(1):55-62. (Pubitemid 47078779)
2. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
3. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033-5043.
4. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89(8):3531-3535.
5. Haberichter SL, Jozwiak MA, Rosenberg JB, Christopherson PA, Montgomery RR. The von Willebrand factor propeptide (VWFpp) traffics an unrelated protein to storage. Arterioscler Thromb Vasc Biol. 2002;22(6):921-926. (Pubitemid 34655218)
6. Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J. 1987;6(10):2885-2890.
7. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell. 1988;52(2):229-236. (Pubitemid 18043596)
8. Haberichter SL, Allmann AM, Jozwiak MA, Montgomery RR, Gill JC. Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage. J Thromb Haemost. 2009;7(4):641-650.
9. Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem. 1989;264(23):13497-13503. (Pubitemid 19198428)
10. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986;102(4):1320-1324. (Pubitemid 16038076)
11. Rosenberg JB, Haberichter SL, Jozwiak MA, et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood. 2002;100(5):1699-1706. (Pubitemid 34925147)
12. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46(2):185-190. (Pubitemid 16031685)
13. Weibel ER, Palade GE. New Cytoplasmic Components in Arterial Endothelia. J Cell Biol. 1964;23:101-112.
14. Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler DF. Formation and function of Weibel-Palade bodies. J Cell Sci. 2008;121(pt 1):19-27. (Pubitemid 351265699)
15. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76(3):1102-1106. (Pubitemid 16225558)
16. Cramer EM, Meyer D, le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that ofWeibel-Palade bodies. Blood. 1985;66(3):710-713. (Pubitemid 15230782)
17. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987;84(7):1955-1959. (Pubitemid 17054128)
18. Hannah MJ, Skehel P, Erent M, Knipe L, Ogden D, Carter T. Differential kinetics of cell surface loss of von Willebrand factor and its propolypeptide after secretion fromWeibel-Palade bodies in living human endothelial cells. J Biol Chem. 2005;280(24):22827-22830. (Pubitemid 40853189)
19. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83(12):3536-3544. (Pubitemid 24175543)
20. Ulrichts H, Udvardy M, Lenting PJ, et al. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem. 2006;281(8):4699-4707. (Pubitemid 43847729)
21. Zhao Y, Dong N, Shen F, et al. Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost. 2007;5(9):1963-1970. (Pubitemid 47288956)
22. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
23. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10):4979-4985.
24. Singh I, Shankaran H, Beauharnois ME, Xiao Z, Alexandridis P, Neelamegham S. Solution structure of human von Willebrand factor studied using small angle neutron scattering. J Biol Chem. 2006;281(50):38266-38275. (Pubitemid 46041950)
25. Dayananda KM, Gogia S, Neelamegham S. Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Forster resonance energy transfer proteins that quantify ADAMTS13 activity. Anal Biochem. 2011;410(2):206-213.
26. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shearinduced platelet activation and self-association of von Willebrand factor in suspension. Blood. 2003;101(7):2637-2645. (Pubitemid 36857624)
27. Lahiri J, Isaacs L, Tien J, Whitesides GM. A strategy for the generation of surfaces presenting ligands for studies of binding based on an active ester as a common reactive intermediate: a surface plasmon resonance study. Anal Chem. 1999;71(4):777-790.
28. Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor selfassociation on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood. 2010;116(19):3990-3998.
29. Myszka DG, Morton TA. CLAMP: a biosensor kinetic data analysis program. Trends Biochem Sci. 1998;23(4):149-150.
30. Ahmed F, Alexandridis P, Shankaran H, Neelamegham S. The ability of poloxamers to inhibit platelet aggregation depends on their physicochemical properties. Thromb Haemost. 2001;86(6):1532-1539. (Pubitemid 34007529)
31. Neeves KB, Maloney SF, Fong KP, et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost. 2008;6(12):2193-2201.
32. Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem. 2004;279(48):49982-49988. (Pubitemid 39577807)
33. Huang RH, Wang Y, Roth R, et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A. 2008;105(2):482-487. (Pubitemid 351171734)
34. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-12109. (Pubitemid 38445774)
35. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114. (Pubitemid 44403432)
36. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost. 2009;7 Suppl 1:65-70.
37. Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage. Blood. 2003;101(4):1384-1391. (Pubitemid 36182510)
38. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996;88(8):2951-2958. (Pubitemid 26357375)
39. van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 1999;94(1):179-185. (Pubitemid 29300147)
40. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266(32):21948-21955. (Pubitemid 121000273)
41. Bendetowicz AV, Morris JA, Wise RJ, Gilbert GE, Kaufman RJ. Binding of factor VIII to von willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers. Blood. 1998;92(2):529-538. (Pubitemid 28323716)
42. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood. 2008;111(2):651-657.
43. Castaman G, Montgomery RR, Meschengieser SS, Haberichter SL,Woods AI, Lazzari MA. von Willebrand's disease diagnosis and laboratory issues. Haemophilia. 2010;16(suppl 5):67-73.
44. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost. 2007;5(7):1363-1370. (Pubitemid 46965360)
45. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A. 2004;101(29):10578-10583. (Pubitemid 38955784)
46. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A. 2008;105(21):7416-7421. (Pubitemid 351830032)